Incivek versus Victrelis in hepatitis C virus treatment: US physician views

10 April 2012

For the treatment of hepatitis C virus (HCV), the majority of surveyed US physicians  survey by advisory company Decision Resources who prescribe the Vertex (Nasdaq: VRTX) protease inhibitor Incivek (telaprevir) more often than the protease inhibitor Victrelis (boceprevir) from Merck & Co (NYSE: MRK) and Roche (ROG: SIX) perceive Incivek as offering a short, simple treatment duration and superior efficacy.

Similarly, surveyed managed care organizations’ (MCOs) pharmacy directors indicate that Incivek’s efficacy is the key driver of formulary inclusion. Physicians’ perception for sustained virologic response (SVR) as a key driver of prescribing for Incivek may suggest that emerging therapies with a higher SVR rate are likely to take patient share from Incivek unless they fall significantly short on other attributes such as safety or convenience.

The new US Physician & Payer Forum report, titled A New Era in the Treatment of Hepatitis C Virus: What Market Access Hurdles Are US Payers Erecting and How Are Physicians Responding? also finds that more surveyed physicians report that their HCV patients request treatment with Incivek over Victrelis. Although most surveyed physicians report that their HCV patients have not requested treatment with a specific protease inhibitor, requests for Incivek are more common than requests for Victrelis among physicians whose patients request a specific protease inhibitor.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical